Supplemental Table 1: Odds ratio for SVR12

|  |  |  |
| --- | --- | --- |
|   | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
| Age | 1.02 (1.00-1.05) | 1.04 (1.00-1.07) |
| Race/Ethnicity |   |   |
| White† | 1.32 (0.90-1.94) | -- |
| African American | 0.77 (0.54-1.11) | 0.43 (0.27-0.69) |
| Hispanic | 0.69 (0.43-1.09) | 0.73 (0.33-1.64) |
| Asian | 0.89 (0.11-7.44) | 0.35 (0.04-3.43) |
| Other | 0.88 (0.19-4.01) |  |
| Treatment Naïve | 1.44 (0.95-2.17) | 1.46 (0.90-2.37) |
| HCV Genotype |   |   |
| 1a† | 1.18 (0.82-1.69) | -- |
| 1b | 1.43 (0.92-2.22) | 1.02 (0.54-1.92) |
| 2 | 0.5 (0.29-0.88) | 2.47 (0.25-24.5) |
| 3 | 0.46 (0.26-0.83) | 0.32 (0.09-1.04) |
| 4‡ | -- | -- |
| 6‡ | -- | -- |
| Fib4 ≥3.25 | 0.4 (0.28-0.58) | 0.40 (0.26-0.68) |
| Treatment Regimen |   |   |
| PrOD | 1.66 (0.58-4.70) | 0.76 (0.19-2.91) |
| PrOD/ Ribavirin (RBV) | 0.86 (0.54-1.35) | 0.41 (0.18-0.95) |
| Sofosbuvir/Ledipasvir† | 2.94 (1.83-4.68) | -- |
| Sofosbuvir/Ledipasvir /RBV  | 0.96 (0.57-1.62) | 0.80 (0.29-2.18) |
| Sofosbuvir/RBV | 0.41 (0.25-0.67) | 0.05 (0.01-0.47) |
| Sofosbuvir/Simeprevir  | 0.52 (0.34-0.79) | 0.10 (0.02-0.58) |
| HIV  | 1.44 (0.43-4.80) | 1.77 (0.48-6.65) |
| Duration of Treatment |   |   |
| 8 weeks | 2.41 (1.35-4.28) | 0.84 (0.33-2.12) |
| 12 weeks† | 0.83 (0.55-1.27) | -- |
| 16 weeks | 0.21 (0.10-0.44) | 0.24 (0.08-0.73) |
| 24 weeks | 0.77 (0.33-1.77) | 3.43 (0.50-23.9) |
| Obese | 0.90 (0.62-1.31) | 1.25 (0.82-1.90) |
| HTN | 1.06 (0.74-1.52) | 0.81 (0.51-1.28) |
| HLD | 1.42 (0.97-2.10) | 1.31 (0.87-1.97) |
| T2DM | 0.72 (0.48-1.10) | 0.82 (0.55-1.09) |
| Metabolic Syndrome | 1.04 (0.68-1.60) | 1.81 (0.75-4.37) |

HCV- Hepatitis C Virus; HIV-Human Immunodeficiency Virus; HTN-Hypertension; HLD-Hyperlipidemia, OR-Odds Ratio; SVR12- Sustained Virologic Response 12 weeks post-treatment, PrOD- Ombitasvir/Paritaprevir/Ritonavir/ Dasabuvir,

†Reference group, ‡Had no failures and so OR could not be calculated